Gordon, R., Xu, T., & Xie, L. (2012). Brazil’s health insurance.
http://www.google.com/search?safe=active&rlz=1T4MXGB_enUS546&q=Ronald+Gordon+and+Tian+Xu&oq=Ronald+Gordon+and+Tian+Xu&
gs_l=serp.12..0i22i30.24027.62191.0.63861.56.40.0.0.0.0.3339.10282.0j1j4j2j6-1j0j1j2.11.0....0...1c.1.22.serp..46.10.10048.q8uuFXd4Z8s

has been cited by the following article:

• TITLE: Financing Innovative Medicines in Mainland China: The Role of Commercial Health Insurance

  AUTHORS: Hong Li, Gordon G. Liu, Christoph Glaetzer

  KEYWORDS: Mainland China; NRDL; Innovative Medicines; Commercial Health Insurance;

  JOURNAL NAME: Chinese Studies, Vol.2 No.3, August 6, 2013

  ABSTRACT: The National Reimbursement Drug List (NRDL) is a key component of the current government-led insurance policy to provide access to basic medicines in mainland China; yet NRDL coverage is limited due to public budgetary constraints and new, innovative medicines are often excluded. This paper explores the potential role of commercial health insurance as an optional approach to financing medicines excluded by the NRDL. The current status of commercial health insurance (CHI) in Mainland China is reviewed and we discuss proposed changes that may be needed to develop an effective and sustainable commercial insurance program to provide the Chinese population with better access to innovative medicines not covered by NRDL.